TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05535998
Drug: Targeted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: The TKI therapy used in this study were lenvatinib (12 mg/d for bodyweight ⩾ 60 kg or 8 mg/d for bodyweight \<60 kg), sorafenib (400 mg twice a day) or apatinib (250-500 mg orally once daily). Administration of lenvatinib, apatinib or sorafenib was started on the first post-TACE day, and continually administered until disease progression developed or serious treatment-related toxicity occurred.
Study: NCT05841654
Drug: Azilsartan or antihypertensive drugs other than ACEI, ARB or ARNI
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient's ECG information will be monitored through the ECG monitoring patch, and the time of the first atrial fibrillation event will be recorded. Monitoring whether the patient's blood pressure is controlled dynamically, using echocardiography to evaluate cardiac function, and using scales to assess the quality of life.
Study: NCT04682405
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Provided by study
Study: NCT06021145
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 26-week use of automated insulin delivery system with placebo (daily) in individuals with suboptimal time in range.
Study: NCT05325515
Drug: Effervescent and buffered alendronate
Normalized name: alendronate Effervescent Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effervescent and buffered alendronate 70mg weekly
Study: NCT05665270
Drug: Dextenza 0.4Mg Ophthalmic Insert
Normalized name: Dextenza 0.4mg Ophthalmic Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 (20 eyes) will receive treatment with topical 1% Prednisolone Acetate drops QID x 1 week, then Dextenza will be inserted at the one-week postoperative evaluation (Day 8). Both groups will receive topical Prolensa Qa.m. x 5 weeks and Moxifloxacin TID x 1 week, per investigators preferential treatment regimen.
Study: NCT05665270
Drug: Prednisolone Acetate 1%
Normalized name: PREDNISOLONE ACETATE 1% SUSP,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2 (20 eyes) will receive treatment with topical 1% Prednisolone Acetate for five weeks with dosing schedule: QID x 2 weeks, TID x 1 week, BID x 1 week, QD x 1 week.~Both groups will receive topical Prolensa Qa.m. x 5 weeks and Moxifloxacin TID x 1 week, per investigators preferential treatment regimen.
Study: NCT06310538
Drug: Hongjin Xiaojie Capsules
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The main group of HongjinXiaojie capsule is divided into anisanglian, Bupleurum, Notoginseng, golden buckwheat, Xiangfu, chicken Yanteng, etc., which has the effect of soft and hard dispersing knot, soothing liver and regulating Qi, promoting blood circulation and removing blood stasis, reducing swelling and relieving pain, and has a certain effect on the treatment of mammary hyperplasia
Study: NCT05032560
Drug: ABX464
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: ABX464 ABX464 is a new anti-inflammatory drug
Study: NCT05032560
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Matching Placebo placebo matching with ABX464
Study: NCT06296966
Drug: VSJ-110
Approvals — FDA: no, EMA: no, PMDA: no
Description: ophthalmic solution
Study: NCT06296966
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: ophthalmic solution
Study: NCT05888350
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Placebo, 1puff, BID, 4weeks
Study: NCT04840615
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion related reactions precaution: All participants will be premedicated with 650 mg Acetaminophen by mouth (PO) or intravenous (IV) 30-60 minutes (+ 30 minutes) prior to each LMB-100 administration.
Study: NCT05229601
Drug: HFB301001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose Escalation: Participants will be administered dose level 1 in Cohort 1. Participants in Cohorts 2-4 will receive dose levels 2-4, respectively.~Dose Expansion: Participants with certain cancer types will be administered the dose determined at dose escalation.
Study: NCT00000950
Drug: Pyridoxine hydrochloride
Normalized name: Pyridoxine Hydrochloride
DrugBank: Pyridoxine phosphate (DB02209)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06278090
Drug: Ursodeoxycholic Acid Only Product
Normalized name: Ursodeoxycholic acid only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid treatment, 10-15mg/kg/day for at least 6 months
Study: NCT05872841
Drug: Recombinant human adenovirus type 5 + TACE
Normalized name: adenovirus, type 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Recombinant human adenovirus type 5 : Recombinant human adenovirus type 5 injection is administered intratumorally 48-72h prior to TACE treatment.Before administration, the recombinant human adenovirus type 5 injection was diluted to 30% of the total tumor volume with normal saline. H101 dose:~   ① The sum of the maximum diameters of the lesions was ≤10cm, and the total dose was 1. 0×1012vp (2 injections);~   ② The sum of the maximum diameters of the lesions was \>10cm, and the total dose was 1. 5×1012vp (3 injections);~2. TACE：The specific chemotherapeutic drugs were: oxaliplatin 85mg/m2, calcium folinic acid 400mg/m2, 5-fluorouracil 1200mg/m2, followed by superfluid iodinated oil bolus according to the intraoperative contrast tumor blood supply.~Recombinant human adenovirus type 5 was administered in combination with TACE in cycles of every 3 weeks for a total of 2-4 cycles.
Study: NCT06345300
Drug: Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate in combination with Camrelizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treatment regimen for this study is as follows:~Intravenous infusion of Oxaliplatin at a dose of 85mg/m2 for 2 hours or according to clinical practice at the research center;~Intravenous infusion of liposomal Irinotecan at a dose of 60mg/m2 for 90 minutes (±30 min);~Intravenous drip of Calcium folinate at a dose of 400mg/m2 for 30 minutes or according to clinical practice at the research center;~Intravenous infusion of 5-Fluorouracil at a dose of 2400mg/m2 (infused for 46-48 hours or according to clinical practice at the research center);~Camrelizumab at a fixed dose of 200mg, administered via intravenous drip, with each infusion lasting no less than 30 min and no more than 60 min. Administered on day 1 of every 2-week cycle (d1, q2w).~Each treatment cycle is 14 days, and all drugs are administered on day 1.
Study: NCT04653493
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04231643
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: one-time oral administration of placebo
Study: NCT06203080
Drug: ancetate gel
Normalized name: acetic acid Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: An acetic acid thermoreversible gel produced by Shanghai Jinxiang Latex Products Co. will be utilized for the intervention. Each product weighs 4.85 g and contains 54.45 mg of poloxamer 407-acetic acid. The investigators will stockpile the product and distribute a total of 72 doses on the first day, at the end of the second month, and at the end of the fourth month of follow-up, respectively, after concealing the product's name. Participants will receive instructions to apply the medication transvaginally, one dose at a time, during each instance of sexual activity.
Study: NCT06345300
Drug: Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treatment regimen for this study is as follows:~Intravenous infusion of Oxaliplatin at a dose of 85mg/m2 for 2 hours or according to clinical practice at the research center;~Intravenous infusion of liposomal Irinotecan at a dose of 60mg/m2 for 90 minutes (±30 min);~Intravenous drip of Calcium folinate at a dose of 400mg/m2 for 30 minutes or according to clinical practice at the research center;~Intravenous infusion of 5-Fluorouracil at a dose of 2400mg/m2 (infused for 46-48 hours or according to clinical practice at the research center); Each treatment cycle is 14 days, and all drugs are administered on day 1.
Study: NCT05477810
Drug: Treatment A (investigational drug) followed by Treatment B (reference drug)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two drug administration periods (1 and 2), each consisting of administration of Treatment A (investigational drug) followed by Treatment B (reference drug) on Day 1 will be performed. Post administration of the study drug standard PK sampling, measurement of vital signs, adverse events, ECG and VAS as per schedule will be done over a time period of 11 hours. The study participants will thereafter be discharged. The participants will return to the study center at 24, 48, 72 and 96 hours after study drug administration in each treatment period for blood sampling, vital signs and safety assessments as per schedule. The wash-out period between doses will be at least 7 days.
Study: NCT05477810
Drug: Treatment B (reference drug) followed by Treatment A (investigational drug)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two drug administration periods (1 and 2), each consisting of administration of Treatment B (reference drug) followed by Treatment A (investigational drug) or on Day 1 will be performed. Post administration of the study drug standard PK sampling, measurement of vital signs, adverse events, ECG and VAS as per schedule will be done over a time period of 11 hours. The study participants will thereafter be discharged. The participants will return to the study center at 24, 48, 72 and 96 hours after study drug administration in each treatment period for blood sampling, vital signs and safety assessments as per schedule. The wash-out period between doses will be at least 7 days.
Study: NCT05895747
Drug: Low Dose Creatine Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine monohydrate 5g PO qday
Study: NCT05895747
Drug: High Dose Creatine Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine monohydrate 10g PO qday
Study: NCT05895747
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine-matched placebo and 5-HTP-matched placebo; Placebo will be dextrose either encapsulated (5-HTP matched) or as loose powder (creatine matched)
Study: NCT05320120
Drug: 0.9% saline solution nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline solution nasal spray
Study: NCT06307288
Drug: minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patient was treated with oral minocycline, 50mg each time, once a day, for 12 weeks.
Study: NCT05196945
Drug: Esomeprazole +Amoxicillin+Clarithromycin+Bismuth potassium citrate
Normalized name: lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Esomeprazole 20mg/ time, 2 times/day, oral Amoxicillin 1g/ time, 2 times/day, oral Clarithromycin 0.5g/ time, 2 times/day, oral Bismuth potassium citrate 220mg/ time, twice a day, orally
Study: NCT04603690
Drug: Standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: This arm will receive standard of care as per the hospital guidelines
Study: NCT05834751
Drug: PEG-rhG-CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 48-72 hours after chemotherapy,9 mg of PEG-rhG-CSF was injected subcutaneously for mobilization
Study: NCT05745363
Drug: AL2846 capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: AL2846 is a multi-target tyrosine kinase inhibitor
Study: NCT05333107
Drug: NNC0385-0434 G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive oral dose of NNC0385-0434 G tablet either for the initial 10-day treatment period (period 1) or 5-day treatment period (period 2).
Study: NCT05333107
Drug: NNC0385-0434 F
Normalized name: F
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive oral dose of NNC0385-0434 F tablet either for the initial 10-day treatment period (period 1) or 5-day treatment period (period 2).
Study: NCT05333107
Drug: NNC0385-0434 B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive oral dose of NNC0385-0434 B tablet either for the initial 10-day treatment period (period 1) or 5-day treatment period (period 2).
Study: NCT06468254
Drug: Statin
Normalized name: Statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin Group: Conventional chemotherapy and maintenance therapy combined with statins.
Study: NCT05954806
Drug: Antivenom Snakes
Approvals — FDA: no, EMA: no, PMDA: no
Description: No specific antivenom exists for a bite by Hypnale hypnale yet most patients are treated with non-specific antivenoms, risking reactions without hope of benefit. In this study we compare patients With Hypnale Hypnale Bite receiving Antivenom vrs patients With Hypnale Hypnale Bite not receiving Antivenom.
Study: NCT06153329
Drug: THDB0206 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 U/kg, single-dose administration, subcutaneous injection 5 cm laterally from the belly button on the left or right side of the abdominal wall
Study: NCT06153329
Drug: Humalog®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 U/kg, single-dose administration, subcutaneous injection 5 cm laterally from the belly button on the left or right side of the abdominal wall
Study: NCT04786990
Drug: SPN-812
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viloxazine extended-release capsule
Study: NCT04847947
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule Placebo containing white rice flour in the same identical looking with active drug once daily and Calcium Lactate 500 mg once daily for 12 weeks
Study: NCT04392999
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of corticosteroid into the cervical facet joints.
Study: NCT05084963
Drug: IRL201104
Approvals — FDA: no, EMA: no, PMDA: no
Description: lyophilised powder for reconstitution for IV dosing
Study: NCT05084963
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo for IRL201104
Study: NCT05805904
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT06441591
Drug: Standard Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-hypertensive and anti-diabetic medications according to the the institution's protocol
Study: NCT05376085
Drug: DA-5215-R Tab
Normalized name: R
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral administration of 1 tablet of DA-5215-R Tab with 150mL water
Study: NCT05950490
Drug: Intravitreal injection of methotrexate
Normalized name: methotrexate Injection
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravitreal injection of methotrexate:400ug/0.1mL，Once a week\*4 weeks → Once every two weeks\*4 weeks → once a month \*10 times(16 times a year)~Systemic therapy:~Induction period:（Zanubrutinib + Rituximab，ZR） (28 days/cycle) x 6 cycles:Rituximab iv375mg/m2 D1, Zanubrutinib 160mg bid D1-D21; Maintenance treatment:Zanubrutinib 160mg bid x 2 years
Study: NCT04758780
Drug: 89Zr-TLX250 PET/CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pretherapeutic 89Zr-TLX250 PET/CT
Study: NCT05358379
Drug: CYC140
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYC140 is a highly selective, orally- and intravenously- available, ATP-competitive inhibitor of PLK1.
Study: NCT00845689
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl 0,9 %
Study: NCT00845689
Drug: adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous infusion of adenosine 0, 2 %
Study: NCT00845689
Drug: adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous infusion of adenosine 0,2 %
Study: NCT06258356
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline (compared to Remimazolam)
Study: NCT05163691
Drug: 5 Methoxy N,N Dimethyltryptamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH001 administered via inhalation
Study: NCT05163691
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH001 Placebo administered via inhalation
Study: NCT00001006
Drug: AS-101
Normalized name: OXT-101
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06077786
Drug: Placebo to Lu AG06474
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution
Study: NCT06077786
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capsule
Study: NCT06077786
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule
Study: NCT05323981
Drug: HS627(210mg/7ml)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous drip of 420mg HS627
Study: NCT05323981
Drug: HS627(420mg/14ml)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous drip of 420mg HS627
Study: NCT05845723
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive intravenous infusion of cyclophosphamide 0.5g biweekly for 24 weeks.
Study: NCT05192369
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 tablet) dosed with water
Study: NCT05365178
Drug: TQB3616 capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB3616 capsule is a CDK (cyclin-dependent kinases) 4/6 kinase inhibitor, which can selectively inhibit THE activity of CDK4/6 kinase, make it form a complex with Cyclin D, reduce the phosphorylation level of retinoblastoma protein (Rb) in cancer cells, and prevent cells from entering S phase from G1 phase
Study: NCT05365178
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: It is a placebo
Study: NCT05292846
Drug: Direct-acting oral anticoagulation
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban Dabigatran Edoxaban Rivaroxaban
Study: NCT05240456
Drug: Beta3-Agonists, Adrenergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: The beta 3 agonist ,Mirabegron, has been shown to be effective for the treatment of OAB in adults through relaxation of bladder wall, with few side effects. This intervention aims to evaluate its efficacy and safety for children with non-neurogenic voiding dysfunction.
Study: NCT05240456
Drug: Anticholinergic drug, Solifenacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticholinergic drugs are widely used to treat overactive bladder by relaxation of bladder wall smooth muscles.
Study: NCT05392959
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for dapagliflozin film-coated tablets 10 mg
Study: NCT05079529
Drug: β-1,3/1,6-D-Glucan From Mycelia Extract of Indonesia's Ganoderma Lucidum Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Takes β-1,3/1,6-D-Glucan capsule 3 times daily for 90 days
Study: NCT05079529
Drug: Placebo Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Takes placebo capsule 3 times daily for 90 days
Study: NCT05832398
Drug: FOLFOX , FOLFIRI or FOLFOXIRI regimens
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 400mg/m2 infusion, and 2400mg/m2 as a 46-hour continuous infusion on day 1) for 6 cycle FOLFIRI (irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 400mg/m2 infusion, and 2400mg/m2 as a 46-hour continuous infusion on day 1) for 6 cycle FOLFOXIRI (irinotecan 150mg/m2, and folinic acid 400mg/m2, oxaliplatin 85 mg/m2, 5-fluorouracil 3200 mg/m2 48-h continuous infusion) for 6 cycle
Study: NCT05832398
Drug: FOLFOX or CapeOX regimens
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 400mg/m2 infusion, and 2400mg/m2 as a 46-hour continuous infusion on day 1) for 6 cycle CaoeOX (Oxaliplatin 130 mg/m2 intravenous infusion on day 1,Capecitabine 1000 mg/m2 twice daily PO for 14 days)
Study: NCT06446557
Drug: standard management
Approvals — FDA: no, EMA: no, PMDA: no
Description: At least 8 cycles of doublet CT + TA before adaptation of sequence at physician choice.
Study: NCT00625157
Drug: ASF 1096 0.5 % cream
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00625157
Drug: ASF 1096 placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06018116
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT06030843
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo containing Lactose content (0.26 gram)
Study: NCT06258746
Drug: [14C]HSK31679
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single oral dose of 160 mg/100 μCi \[14C\]HSK31679 after fasting for at least 10 hours.
Study: NCT05654831
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo will be administered as oral tablet. Matching Placebo will be given orally during each dosing day.
Study: NCT05654831
Drug: ECC5004
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECC5004 will be administered as oral tablet(s) during each dosing day.
Study: NCT00000938
Drug: doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05841095
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline solution (0.9% NaCl)
Study: NCT06336148
Drug: ACTM-838
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating doses of ACTM-838 in Part 1a and recommended dose in Part 1b
Study: NCT05404490
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL of Normal Saline Solution will be infiltrated. 10 mL will be infiltrated in the inferior border and 10 mL in the superior border of the subcutaneous cellular tissue.
Study: NCT05811247
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration at bedtime.
Study: NCT05218616
Drug: Aviga, capsules 50 mg / Sutent®, capsules 50 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aviga is manufactured by JLLC NATIVITA, Republic of Belarus. Each capsule contains 50 mg of Sunitinib / Sutent® is manufactured by Pfizer Italia S.R.L., Italia. Each capsule contains 50 mg of Sunitinib.
Study: NCT05218616
Drug: Sutent®, capsules 50 mg / Aviga, capsules 50 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sutent® is manufactured by Pfizer Italia S.R.L., Italia. Each capsule contains 50 mg of Sunitinib / Aviga is manufactured by JLLC NATIVITA, Republic of Belarus. Each capsule contains 50 mg of Sunitinib
Study: NCT04540094
Drug: Balanced crystalloid solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any preparation of intravenous balanced crystalloid which has marketing authorisation in the UK to be used for this indication and is stocked by local hospital pharmacies at the participating sites, may be prescribed in this study.
Study: NCT05661591
Drug: SHR2554 Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR2554 Tablets+ Fluconazole Capsules